Patent application number | Description | Published |
20120064089 | ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL16 and/or the chemokine receptor CXCR6. | 03-15-2012 |
20120082993 | DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES - Methods for detecting cancer or monitoring cancer progression in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL16 or CXCR6 or both CXCL16 and CXCR6. Also disclosed is a kit for detecting cancer or monitoring cancer progression. | 04-05-2012 |
20120100154 | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CCL25 and/or the chemokine receptor CCR9. | 04-26-2012 |
20120100554 | DETECTING CANCER WITH ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES - Methods for detecting cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprise CCL25 or CCR9 or both CCL25 and CCR9. | 04-26-2012 |
20120128688 | ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND CANCER CELL MIGRATION - Methods for prevention or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. Another method comprises the step of administering to the subject a therapeutically effective amount of an expression vector that expresses an antibody to the chemokine CXCL13 and/or the chemokine receptor CXCR5. | 05-24-2012 |
20120135415 | DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES - Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression. | 05-31-2012 |
20130045162 | DELIVERY SYSTEM FOR SPECIFICALLY TARGETING CANCER CELLS AND METHOD OF USE THEREOF - Methods for prevention, treatment or inhibition of the growth or metastasis of cancer cells in a subject are disclosed. One method comprises the step of administering to the subject a therapeutically effective amount of tumor associated antigen binding ligand-coated planetary ball milled (PBM) nanoparticles containing a cytotoxic agent. | 02-21-2013 |
20150126394 | DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES - Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression. | 05-07-2015 |